



1631 \$  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Vaisberg et al.

Attorney Docket No.: CYTOP007

Application No.: 09/311,996

Examiner: Stephen Siu

Filed: May 14, 1999

Group: 1631

Title: A DATABASE SYSTEM INCLUDING  
COMPUTER FOR PREDICTIVE  
CELLULAR BIOINFORMATICS

RECEIVED  
JAN 19 2001  
TECH CENTER 1600/2300

#11  
Plunkett  
9/14/9

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail to: Assistant Commissioner for Patents, Washington, DC 20231 on January 3, 2001.

Signed:

*Leslie Russell*  
Leslie Russell

01/11/2001 TGEDAHU1 00000021 09311996

11 FC:126

180.00 OP

**INFORMATION DISCLOSURE STATEMENT**  
**BEFORE MAILING DATE OF EITHER A FINAL ACTION OR**  
**NOTICE OF ALLOWANCE (37 CFR 1.97(c))**

Assistant Commissioner for Patents  
Washington, DC 20231

Dear Sir:

Refund Ref: 01/11/2001 TGEDAHU1 0000100990 ME

CHECK Refund Total: \$60.00

The reference listed in the attached PTO Form 1449, a copy of which is attached, may be material to examination of the above-identified patent application. Applicants submit this reference in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make this citation of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that this reference indeed constitutes prior art.

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits, or after three months of the filing date of this national application or the date of entry of the national stage as set forth in §1.491 in an international application, whichever event occurred last, but it is believed, before the mailing date of either (1) a final action under §1.113 or (2) a notice of allowance under §1.311, whichever occurs first.

Accompanying this Information Disclosure Statement is:



a statement as specified in 37 CFR 1.97(e).



the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under §1.97(c). (\$240.00).

If it is determined that any additional fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500388 (Order No. CYTOP007).

Respectfully submitted,

BEYER WEAVER & THOMAS, LLP



Jeffrey K. Weaver

Registration No. 31,314

P.O. Box 778  
Berkeley, CA 94704-0778



RECEIVED

JAN 19 2001

TECH CENTER 1600/2400